Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole vs Prednisolone in Allergic Bronchopulmonary Aspergillosis
NCT01621321Phase 3Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jun 2013
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of voriconazole in allergic bronchopulmonary aspergillosis (ABPA) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Response rates in the two groups at 3 months and Relapse rates in the two groups at 24 months. Started Jun 2013; status: completed.
02
Drugs
voriconazole
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT01621321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621321.